Both Semaglutide and Mounjaro represent innovative approaches to managing type 2 diabetes, and increasingly, obesity. Tirzepatide is a twin agonist that impacts two receptors involved in blood sugar control: this peptide and GIP. It, often viewed as a brand name for Semaglutide, acts similarly, o